Table 3.

Non‐Hodgkin's lymphoma (NHL) incidence (annualized %) and HRs by statin use

					Age adjusted				Multivariable adjusted
	N	NHL	Annualized %	Mean fup (year)	Hazard ratio	Lower CL	Upper CL	P‐value	Hazard ratio	Lower CL	Upper CL	P‐value
Statin use
No	14,9338	1011	0.05	12.57	1.00			0.38	1.00			0.18
Yes	12,225	80	0.06	11.82	0.90	0.72	1.14		0.85	0.67	1.08
Statin type
No statin use	14,9338	1011	0.05	12.57	1.00				1.00
Atorvastatin	957	3	0.03	10.85	0.45	0.14	1.39	0.16	0.45	0.14	1.40	0.17
Fluvastatin	1484	8	0.05	11.59	0.75	0.37	1.50	0.41	0.65	0.31	1.38	0.26
Lovastatin	3197	24	0.06	12.25	1.01	0.67	1.52	0.96	0.91	0.59	1.40	0.67
Pravastatin	2683	20	0.06	11.80	1.03	0.66	1.60	0.90	0.94	0.59	1.51	0.81
Simvastatin	3585	22	0.05	11.82	0.86	0.56	1.31	0.47	0.87	0.57	1.32	0.50
Lipophilicity
No statin use	14,9338	1011	0.05	12.57	1.00				1.00
Lipophilic	9223	57	0.05	11.83	0.85	0.65	1.11	0.24	0.80	0.61	1.06	0.13
Hydrophilic	2683	20	0.06	11.80	1.03	0.66	1.60	0.90	0.94	0.59	1.51	0.81
Statin potency
No statin use	14,9338	1011	0.05	12.57	1.00				1.00
Low (Lovastatin, Fluvastatin)	4681	32	0.06	12.04	0.93	0.65	1.32	0.68	0.83	0.57	1.21	0.33
Medium (Pravastatin)	2683	20	0.06	11.80	1.03	0.66	1.60	0.90	0.94	0.59	1.51	0.81
High (Simvastatin, Atorvastatin)	4542	25	0.05	11.62	0.77	0.52	1.15	0.20	0.78	0.52	1.16	0.22
Statin duration
0	14,9338	1011	0.05	12.57	1.00				1.00
1–<3 year	4023	28	0.06	11.90	0.96	0.66	1.39	0.82	0.87	0.59	1.30	0.50
<1 year	3987	18	0.04	11.74	0.64	0.40	1.02	0.06	0.58	0.35	0.95	0.03
≥3 year	3896	31	0.07	11.84	1.08	0.75	1.54	0.69	1.05	0.73	1.51	0.79

Stratified by trial, WHI extension study, and age group.

Base model was adjusted by age.

Multivariable model adjusted for age, history of lupus, history of rheumatoid arthritis, current medical care provider.